Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in alzheimer's disease without cross-reactivity with other protein aggregates

Journal of Alzheimer's Disease

Volumn 29, Issue 2, 2012, Pages 361-371

  Venkataramani, Vivek ^a   Wirths, Oliver ^a   Budka, Herbert ^b   Härtig, Wolfgang ^c   Kovacs, Gabor G ^b   Bayer, Thomas A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimer's disease; amyloid; antibodies; conformation dependent oligomers; immunohistochemistry; N truncated Abeta; neurodegenerative disease; proteinopathy; pyroglutamate

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9D5; OLIGOMER; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY SPECIFICITY; ARGYROPHILIC GRAIN DISEASE; ARTICLE; BINSWANGER ENCEPHALOPATHY; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; CROSS REACTION; DIFFUSE LEWY BODY DISEASE; ENTORHINAL CORTEX; FEMALE; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR WEIGHT; MULTIPLE SYSTEMIC ATROPHY; NEOCORTEX; NERVE DEGENERATION; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; SENILE PLAQUE;

EID: 84859408039     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111379     Document Type: Article

References (45)

1. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
2. Kovacs GG, Botond G, Budka H (2010) Protein coding of neurodegenerative dementias: The neuropathological basis of biomarker diagnostics. Acta Neuropathol 119, 389-408.
3. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118, 5-36.
4. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
5. Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59, 733-748. (Pubitemid 30626743)
6. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800. (Pubitemid 34663580)
7. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112. (Pubitemid 46432529)
8. Walsh DM, Selkoe DJ (2007) A beta oligomers-a decade of discovery. J Neurochem 101, 1172-1184.
9. Margittai M, Langen R (2008) Fibrils with parallel in-register structure constitute a major classofamyloid fibrils: Molecular insights from electron paramagnetic resonance spectroscopy. Q Rev Biophys 41, 265-297.
10. Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurode-generative diseases: New concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1, 151-170.
11. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev 90, 465-494.
12. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224. (Pubitemid 32204378)
13. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791. (Pubitemid 35231524)
14. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phos-phorylation, glial activation, and neuronal loss in vivo. J Neurosci 30, 4845-4856.
15. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta (1-42) into globular neurotoxins. Biochemistry 42, 12749-12760. (Pubitemid 37385806)
16. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shep-ardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
17. Klein WL (2002) Abetatoxicityin Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352.
18. Hartig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J (2010) Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J Chem Neuroanat 40, 82-92.
19. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3 (pE), in senile plaques. Neuron 14, 457-466.
20. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118, 487-496.
21. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glu-taminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 14, 1106-1111.
22. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA (2010) Identification of low molecular weight pyroglutamate Abeta oligomersinAlzheimer disease:Anovel tool for therapy and diagnosis. J Biol Chem 285, 41517-41524.
23. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogen-esis. Science 300, 486-489. (Pubitemid 36444329)
24. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18.
25. Kovacs GG, Budka H (2010) Current concepts of neuropatho-logical diagnostics in practice: Neurodegenerative diseases. Clin Neuropathol 29, 271-288.
26. Kovacs GG, Budka H (2009) Molecular pathology of human prion diseases. Int J Mol Sci 10, 976-999.
27. Kovacs GG, Gelpi E, Lehotzky A, Hoftberger R, Erdei A, Budka H, Ovadi J (2007) The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 113, 153-161. (Pubitemid 46158148)
28. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Cec-carelli C, Pieri F, Fraternali-Orcioni G, Pileri SA (1998) The EnVision++ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, Chem Mate, CSA, LABC, and SABC techniques. J Clin Pathol 51, 506-511. (Pubitemid 28375029)
29. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-6453.
30. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 4077-4081.
31. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005) Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95, 834-847. (Pubitemid 41567174)
32. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
33. O'Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99, 1485-1490. (Pubitemid 34136519)
34. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79, 595-605. (Pubitemid 33029933)
35. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets 8, 65-81.
36. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid beta-peptides-AbetaN3 (pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 82, 1480-1489.
37. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393-12399. (Pubitemid 44583682)
38. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA (2010) Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 117, 85-96.
39. Jawhar S, Wirths O, Bayer TA (2011) Pyroglutamate Abeta-a hatchet man in Alzheimer disease. J Biol Chem 286, 38825-38832.
40. Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ (2002) Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging 23, 161-170. (Pubitemid 34137089)
41. Yamashita S (2007) Heat-induced antigen retrieval: Mechanisms and application to histochemistry. Prog Histochem Cytochem 41, 141-200. (Pubitemid 46013929)
42. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200. (Pubitemid 39492046)
43. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Mil-ner TA, Gouras GK (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24, 3592-3599. (Pubitemid 38481116)
44. Solomon B, Frenkel D (2010) Immunotherapy for Alzheimer's disease. Neuropharmacology 59, 303-309.
45. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neu-ropathology after active Abeta42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384.